SCHEMBL31014248

SCHEMBL31014248

COc1cncc(-c2nccs2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 1/20 0.51
CYP2A6 P11509 1/20 0.49
CYP1A1 P04798 3/20 0.46
CYP1B1 Q16678 3/20 0.46
CYP11B1 P15538 6/20 0.45
CYP11B2 P19099 6/20 0.45
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
PDPK1 O15530 1/20 0.42
MKNK2 Q9HBH9 2/20 0.41
MKNK1 Q9BUB5 1/20 0.41
SRC P12931 1/20 0.41
ZAP70 P43403 1/20 0.41
SYK P43405 1/20 0.41
FYN P06241 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153302 0.77 CYP2A6 (0.54) SMPD3CYP2A6CYP11B1CYP11B2CYP3A4
SCHEMBL1980934 0.77 DYRK1A (0.57) SMPD3CYP2A6CYP1A1CYP1B1CYP1A2
SCHEMBL29462071 0.77 DYRK1A (0.57) SMPD3CYP2A6CYP1A1CYP1B1CYP1A2
SCHEMBL5702666 0.75 CYP1A1 (0.74) CYP1A1CYP1B1CYP11B1CYP11B2CYP1A2
SCHEMBL468161 0.75 PDPK1 (0.57) SMPD3CYP2A6PDPK1ABL1BCR
SCHEMBL2715410 0.74 CYP2A6 (0.53) SMPD3CYP2A6CYP11B1CYP11B2PDPK1
SCHEMBL3386179 0.74 CYP2A6 (0.53) SMPD3CYP2A6CYP1A1CYP1B1CYP11B1
SCHEMBL252833 0.74 CYP2A6 (0.53) SMPD3CYP2A6CYP1A1CYP1B1CYP11B1
SCHEMBL14908855 0.74 CYP2A6 (0.53) SMPD3CYP2A6CYP11B1CYP11B2PDPK1
Hydrochloric Acid SCHEMBL27523094 0.74 PDPK1 (0.55) SMPD3PDPK1ABL1BCRGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US claimed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US claimed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 SMPD3 1499/4885CYP2A6 3441/4885CYP1A1 1779/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 SMPD3 1499/4885CYP2A6 3441/4885CYP1A1 1779/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 SMPD3 1499/4885CYP2A6 3441/4885CYP1A1 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.